| ［1］ Lee SE, Lim JY, Kim TW, et al. Different role of circulating myeloidderived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation［J］. J Immunother Cancer, 2019, 7(1): 35. DOI: 10.1186/s40425-018-0491-y.
［2］ Kaczmarek M, Nowicka A, Kozlowska M, et al. Evaluation of the phenotype pattern of macrophages isolated from malignant and nonmalignant pleural effusions［J］. Tumour Biol, 2011, 32(6): 1123-1132. DOI: 10.1007/s13277-011-0214-1.
［3］ Budna J, Kaczmarek M, KoleckaBednarczyk A, et al. Enhanced suppressive activity of regulatory T cells in the microenvironment of malignant pleural effusions［J］. J Immunol Res, 2018, 2018: 9876014. DOI: 10.1155/2018/9876014.
［4］ Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation［J］. J Immunol, 2002, 168(9): 4272-4276. DOI: 10.4049/jimmunol.168.9.4272.
［5］ Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity［J］. Int Immunol, 2016, 28(8): 401-409. DOI: 10.1093/intimm/dxw025.
［6］ DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma［J］. Cancer Biol Ther, 2005, 4(3): 342-346.
［7］ Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade［J］. Science, 2018, 359(6382): 1350-1355. DOI: 10.1126/science.aar4060.
［8］ Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1positive, advanced nonsmallcell lung cancer (KEYNOTE010): a randomised controlled trial［J］. Lancet, 2016, 387(10027): 1540-1550. DOI: 10.1016/S0140-6736(15)01281-7.
［9］ Brahmer JR, RodriguezAbreu D, Robinson AG, et al. Healthrelated qualityoflife results for pembrolizumab versus chemotherapy in advanced, PD-L1positive NSCLC (KEYNOTE024): a multicentre, international, randomised, openlabel phase 3 trial［J］. Lancet Oncol, 2017, 18(12): 1600-1609. DOI: 10.1016/S1470-2045(17)306903.
［10］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643.
［11］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of Nivolumab an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-smallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9.
［12］ Tseng YH, Ho HL, Lai CR, et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural esffusion［J］. J Thorac Oncol, 2018, 13(3): 447-453. DOI: 10.1016/j.jtho.2017.10.034. |
